Exercise Oncology

The most evidence-rich integrative intervention — reduces mortality, fatigue, and recurrence risk

Key Points

• ASCO 2022 Clinical Practice Guideline: exercise recommended for all cancer patients during and after treatment (Grade A, Strong recommendation).
• Regular exercise (150 min/week moderate or 75 min vigorous) reduces breast cancer mortality by 24–40%, colon cancer mortality by 23–35%, and prostate cancer progression by 30% in large cohort studies.
• Exercise reduces cancer-related fatigue (meta-analysis effect size d=0.60), anxiety, depression, and cognitive impairment — outperforming drug interventions for fatigue in head-to-head trials.
• Aerobic exercise during chemotherapy reduces cardiotoxicity from anthracyclines and trastuzumab — supported by Phase III trial data (CARDAPAC, HEART).
• Resistance training prevents sarcopenia and preserves bone density in patients on AI, ADT, and corticosteroids.
• Exercise modulates the tumor microenvironment: increases NK cell trafficking to tumor, reduces IGF-1 and estrogen, and enhances immunotherapy efficacy in pre-clinical models.

Mechanisms of Anti-Cancer Effects

Exercise exerts biological effects across multiple hallmarks of cancer, making it arguably the most multitarget oncology intervention available: **Hormonal:** Aerobic exercise reduces circulating estrogen (by 10–20% in obese postmenopausal women), IGF-1, insulin, and leptin — all mitogenic signals relevant to breast, endometrial, colorectal, and prostate cancers. The benefit is greatest in overweight/obese patients where hormonal reduction is largest. **Immune Activation:** Each bout of aerobic exercise mobilizes NK cells and cytotoxic T-lymphocytes from peripheral reservoirs into…

Clinical Evidence for Survival Benefit

**Post-Diagnosis Exercise and Survival:** *Breast Cancer:* The Nurses' Health Study (n=2,987 breast cancer survivors) demonstrated that women meeting physical activity guidelines post-diagnosis had 24% lower breast cancer–specific mortality (HR 0.76) and 41% lower all-cause mortality compared to sedentary survivors. The benefit was consistent across hormone receptor subtypes. A 2019 meta-analysis (40 cohort studies, 100,000+ cancer survivors) confirmed 28% lower all-cause mortality in physically active vs. sedentary breast cancer survivors. *Colon Cancer:* The CALGB 89803 trial (n=832 stage…

ASCO Guidelines and Exercise Prescriptions

**ASCO 2022 Guidelines (Ligibel et al., JCO 2022)** represent the most authoritative current standard: *During Active Treatment:* - Aerobic exercise: 150 min/week moderate-intensity (50–70% HRmax, can hold conversation) OR 75 min/week vigorous-intensity (>70% HRmax) - Resistance training: 2–3 sessions/week, all major muscle groups, 2–3 sets of 8–15 repetitions - Flexibility/balance: Daily stretching; balance training especially important for patients with peripheral neuropathy *Key Modifications:* - Avoid public gyms/pools during nadir (neutropenia) - Resistance training: start with low…